Do I need a prescription for peptides?
For injectable peptides used clinically (such as semaglutide, tesamorelin, or BPC-157 compounded formulations), yes, a prescription is legally required in the United States. Topical or oral peptides sold as cosmetics or supplements do not require a prescription but are not regulated as drugs.
How do I find a legitimate peptide prescriber near me?
Search state medical board directories for licensed MDs or DOs, look for clinics affiliated with A4M or IFM, and verify the prescriber uses an FDA-registered 503A or 503B compounding pharmacy.
Are peptides legal to prescribe in the United States?
Yes, with important caveats. FDA-approved peptide drugs (semaglutide, tesamorelin, bremelanotide) are legal to prescribe. Many others are prescribed as compounded medications under 503A pharmacy regulations. Some peptides, including BPC-157 and TB-500, appear on the FDA's list of substances that may not be compounded, which limits their legal prescribability.
What should I ask a peptide doctor at my first appointment?
Ask which compounding pharmacy they use and whether it is 503A or 503B registered, what lab work they require before prescribing, whether the peptide has human clinical trial data for your indication, what monitoring they provide, and what the total cost including labs and follow-ups will be.
What is the difference between a 503A and 503B compounding pharmacy?
503A pharmacies compound for individual patient prescriptions and are licensed by state boards. 503B outsourcing facilities are FDA-registered, subject to federal cGMP standards, and can produce larger batches. For sterile injectable peptides, a 503B or a 503A with documented sterility testing provides a meaningfully higher quality guarantee.
How much does a peptide prescription typically cost?
An initial consultation ranges from roughly $150 to $400. Compounded injectable peptides often cost $100 to $500 per month depending on the compound and dose. FDA-approved peptide drugs follow standard insurance or cash-pay pricing. Lab work adds additional cost and is often not covered for these indications.
Can a telehealth doctor prescribe peptides?
Yes, in many states. Telehealth prescribers must hold a license in the patient's state, conduct a legitimate medical evaluation, and order appropriate baseline labs. The prescription still routes to a licensed compounding pharmacy. Telehealth peptide clinics face the same regulatory constraints as in-person clinics.
What lab work should a doctor order before prescribing peptides?
For growth hormone secretagogues, a baseline IGF-1 level is standard. For weight-related peptides, metabolic panels, HbA1c, and lipids are appropriate. Thyroid function, testosterone, and a complete blood count may also be relevant depending on the compound. A doctor who skips baseline labs is a red flag.
What are the red flags of a low-quality peptide clinic?
No lab work required before prescribing, no follow-up protocol, inability to name the compounding pharmacy or provide a certificate of analysis, claims that a peptide is "FDA approved" when it is not, and selling peptides directly from the clinic at a markup without a separate pharmacy are all serious red flags.
Will insurance cover peptide therapy?
FDA-approved peptide drugs may be covered if the indication matches the label. Compounded peptides prescribed off-label are almost universally not covered by insurance. Tesamorelin (Egrifta) has FDA approval for HIV-associated lipodystrophy and may be covered in that context.
Is it safe to get peptides online without a doctor?
No. Peptides sold online without a prescription as "research chemicals" are not manufactured under pharmaceutical GMP standards, have no sterility guarantee, and may contain incorrect concentrations or contaminants. Multiple published case reports document infections and adverse events from unregulated injectable peptide sources.
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Falutz J, et al. "Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat." New England Journal of Medicine. 2010;363(13):1218-1228.
- U.S. Food and Drug Administration. "Bulk Drug Substances That May Not Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." FDA.gov. Accessed 2025.
- U.S. Food and Drug Administration. "503B Outsourcing Facilities." FDA.gov. Accessed 2025.
- United States Pharmacopeia. "USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations." USP-NF. 2023 revision.
- National Association of Boards of Pharmacy (NABP). "Pharmacy Verification Programs." NABP.pharmacy. Accessed 2025.
- Federation of State Medical Boards. "DocInfo Physician Lookup Tool." FSMB.org. Accessed 2025.
- American Academy of Anti-Aging Medicine (A4M). "Fellow and Member Directory." A4M.com. Accessed 2025.
- Institute for Functional Medicine. "Find a Practitioner Directory." IFM.org. Accessed 2025.
- Renehan AG, et al. "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." Lancet. 2004;363(9418):1346-1353.
- Sievert LL, et al. "Case series: Adverse events associated with use of unregulated injectable peptide compounds." Clinical Toxicology (general reference to published case literature; consult current PubMed for specific cases).
Footer Disclaimers
Platform: FormBlends is an informational platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified, licensed healthcare provider before beginning any peptide therapy or making changes to your current medical treatment.
Research Compound and Compounded Medication Notice: Several peptides discussed on this page are not FDA-approved drugs and are prescribed, where legal, as compounded preparations under 503A pharmacy regulations. Compounded medications have not been reviewed by the FDA for safety, efficacy, or quality as finished products. Regulatory status for specific compounds may change; verify current status with your prescriber and the FDA.
Results Disclaimer: Individual outcomes from peptide therapy vary. Evidence quality ranges from high (for FDA-approved compounds in their labeled indications) to very low (for preclinical-only compounds). Do not interpret described outcomes as typical or guaranteed.
Trademark Notice: Ozempic, Wegovy, Egrifta, and Vyleesi are registered trademarks of their respective owners. FormBlends has no affiliation with these trademark holders. Brand names are used for identification purposes only.
Related peptide guides
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →